Antibody-Based Therapeutics and Diagnostics for Viral Diseases
Deadline for manuscript submissions: closed (15 July 2023) | Viewed by 5961
Interests: cancer immunotherapy; chimeric antigen receptor T cells; bispecific antibodies; single domain antibody; virus therapy and diagnosis
Monoclonal antibodies (mAbs) are useful tools for the diagnosis and treatment of a variety of viral diseases induced by pre-existing and/or emerging viruses, including SARS-CoV, MERS, SARS-CoV-2, and HIV. Traditionally, the consecutive processes of immunization and hybridoma technology to produce a hybrid cell have been used to identify and overproduce target-specific mAbs. Recent advances in recombinant DNA technology have enabled antibody humanization, the generation of human naïve or synthetic antibody libraries, phage display antibody selection, and overproduction of phage-display-derived mAbs. Currently, despite the recent development of various antibody-based therapeutics and diagnostics for viral diseases, the accumulation of high-frequency mutations in viruses has often weakened the virus neutralization and detection activity of existing viral-protein-specific mAbs. In this Special Issue, we focus on covering novel antibody-based diagnostics and therapeutics including antibodies, nanobodies, aptamers, peptides, and Fc-fusion proteins for timely measures and effective management against viral diseases.
Prof. Dr. Sukmook Lee
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- monoclonal antibody
- bi-/multi-specific antibody
- coronaviruses including SEAR-CoV, MERS-CoV, and SARS-CoV-2
- viral diseases
- platform technology